Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: A systematic literature review

Oncologist

Volumn 17, Issue 4, 2012, Pages 555-568

  Bachet, Jean Baptiste ^a,b   Peuvrel, Lucie ^c   Bachmeyer, Claude ^d   Reguiai, Ziad ^e   Gourraud, Pierre A ^f   Bouché, Olivier ^g   Ychou, Marc ^h   Bensadoun, Rene J ⁱ   Dreno, Brigitte ^c   André, Thierry ^b,j  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b GERCOR   (France)

^c INSERM   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e CH Robert Debré ^*  (France)

^f Methodomics Inc   (France)

^g REIMS UNIVERSITY HOSPITAL   (France)

^h CENTRE VAL D AURELLE   (France)

ⁱ Radiation Oncology Department   (France)

^j HÔPITAL SAINT ANTOINE   (France)

more..

Author keywords

Cancer; Cycline; EGFR inhibitors; Folliculitis; Systematic review

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; LYMECYCLINE; MINOCYCLINE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PLACEBO; PLATINUM; TAXANE DERIVATIVE; TETRACYCLINE; VANDETANIB;

COLORECTAL CANCER; DERMATITIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FOLLICULITIS; HEAD AND NECK CARCINOMA; HUMAN; INCIDENCE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW;

FOLLICULITIS; HUMANS; INCIDENCE; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; TETRACYCLINES;

EID: 84860287213     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0365     Document Type: Review

References (150)

1. Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining? J Clin Oncol 2005;23:5235-5246.
2. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-1552.
3. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 2008;372:1809-1818.
4. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966.
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
6. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537.
7. Van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009;27:2231-2237.
8. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11:21-28.
9. Hecht JR, Mitchell E, Chidiac T et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27:672-680.
10. Jatoi A, Green EM, Rowland KM Jr et al. Clinical predictors of severe cetuximab induced rash: Observations from 933 patients enrolled in North Central Cancer Treatment Group Study N0147. Oncology 2009;77:120-123.
11. Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360: 1408-1417.
12. Wilke H, Glynne Jones R, Thaler J et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL study. J Clin Oncol 2008;26:5335-5343.
13. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
14. Hecht JR, Patnaik A, Berlin J et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007; 110:980-988.
15. Fukuoka M, Yano S, Giaccone G et al. Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-smallcell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21:2237-2246.
16. Soulieres D, Senzer NN, Vokes EE et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22: 77-85.
17. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16:1425-1433.
18. Segaert S, Chiritescu G, Lemmens L et al. Skin toxicities of targeted therapies. Eur J Cancer 2009; 45(suppl 1):295-308.
19. Robert C, Soria JC, Spatz A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.
20. Van Cutsem E, Peeters M, Siena S et al. Openlabel phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25: 1658-1664.
21. Galimont-Collen AF, Vos LE, Lavrijsen AP et al. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 2007;43: 845-851.
22. Agero AL, Dusza SW, Benvenuto-Andrade C et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006;55:657-670.
23. Roé E, Garcia Muret MP, Marcuello E et al. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: A prospective study of 30 patients. J Am Acad Dermatol 2006; 55:429-437.
24. Wacker B, Nagrani T, Weinberg J et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13:3913-3921.
25. Peeters M, Siena S, Van Cutsem E et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 2009;115:1544-1554.
26. Van Cutsem E, Peeters M, Gelderblom H. Cetuximab dose-escalation in mCRC patients with no or slight skin reactions on standard treatment (EVEREST) [abstract O-0034]. Ann Oncol 2007; 18(suppl vii):1-22.
27. Senderowicz AM, Johnson JR, Sridhara R et al. Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology (Williston Park) 2007;21:1696-1706; discussion 1706-1709, 1712, 1715.
28. Pérez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-3247.
29. Bernier J, Bonner J, Vermorken JB et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008;19:142-149.
30. Bonner JA, Ang K. More on severe cutaneous reaction with radiotherapy and cetuximab. N Engl J Med 2007;357:1872-1873.
31. Tejwani A, Wu S, Jia Y et al. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer 2009;115:1286-1299.
32. Jatoi A, Nguyen PL. Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. The Oncologist 2008;13: 1201-1204.
33. Nardone B, Nicholson K, Newman M et al. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients. Clin Cancer Res 2010;16:4452-4460.
34. Joshi SS, Ortiz S, Witherspoon JN et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 2010;116:3916-3923.
35. Boone SL, Rademaker A, Liu D et al. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: Survey results. Oncology 2007;72:152-159.
36. Dreno B, Bettoli V, Ochsendorf F et al. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol 2004;14:391-399.
37. Kircik LH. Doxycycline and minocycline for the management of acne: A review of efficacy and safety with emphasis on clinical implications. J Drugs Dermatol 2010;9:1407-1411.
38. Ochsendorf F. [Systemic antibiotic therapy of acne vulgaris.] J Dtsch Dermatol Ges 2010;8(suppl 1):S31-S46. In German.
39. Burtness B, Anadkat M, Basti S et al. NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw 2009;7(suppl 1):S5-S21; quiz S22-S24.
40. Fervers B, Hardy J, Blanc-Vincent MP, et al. SOR: Project methodology. Br J Cancer 2001; 84(suppl 2):8-16.
41. Jacot W, Bessis D, Jorda E et al. Acneiform eruption induced by epidermal growth factor recep-tor inhibitors in patients with solid tumours. Br J Dermatol 2004;151:238-241.
42. Ocvirk J, Cencelj S. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. J Eur Acad Dermatol Venereol 2010;24:453-459.
43. Lee MW, Seo CW, Kim SW et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 2004;84: 23-26.
44. Busam KJ, Capodieci P, Motzer R et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001;144:1169-1176.
45. Gutzmer R, Werfel T, Mao R et al. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 2005;153:849-851.
46. Moss JE, Burtness B. Images in clinical medicine. Cetuximab-associated acneiform eruption. N Engl J Med 2005;353:e17.
47. Alexandrescu DT, Vaillant JG, Dasanu CA. Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors. Clin Exp Dermatol 2007;32:71-74.
48. Cotena C, Gisondi P, Colato C et al. Acneiform eruption induced by cetuximab. Acta Dermatovenerol Croat 2007;15:246-248.
49. Monti M, Motta S. Clinical management of cutaneous toxicity of anti-EGFR agents. Int J Biol Markers 2007;22(suppl 4):S53-S61.
50. Gencoglan G, Ceylan C. Two cases of acneiform eruption induced by inhibitor of epidermal growth factor receptor. Skin Pharmacol Physiol 2007;20:260-262.
51. Lee JE, Lee SJ, Lee HJ et al. Severe acneiform eruption induced by cetuximab (Erbitux). Yonsei Med J 2008;49:851-852.
52. Patrizi A, Bianchi F, Neri I. Rosaceiform eruption induced by erlotinib. Dermatol Ther 2008; 21(suppl 2):S43-S45.
53. Bovenschen HJ, Alkemade JA. Erlotinib-induced dermatologic side-effects. Int J Dermatol 2009;48:326-328.
54. Acharya J, Lyon C, Bottomley DM. Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin. J Am Acad Dermatol 2009;60:154-157.
55. Scope A, Lieb JA, Dusza SW et al. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol 2009;61:614-620.
56. Katzer K, Tietze J, Klein E et al. Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab-a report of 29 patients. Eur J Dermatol 2010;20:82-84.
57. Kanazawa S, Yamaguchi K, Kinoshita Y et al. Aspirin reduces adverse effects of gefitinib. Anticancer Drugs 2006;17:423-427.
58. Kanazawa S, Yamaguchi K, Kinoshita Y et al. Effect of low-dose aspirin for skin rash associated with erlotinib therapy in patients with lung cancer. Platelets 2009;20:70-71.
59. Herbst RS, LoRusso PM, Purdom M et al. Dermatologic side effects associated with gefitinib therapy: Clinical experience and management. Clin Lung Cancer 2003;4:366-369.
60. Hassel JC, Kripp M, Al-Batran S et al. Treatment of epidermal growth factor receptor antagonistinduced skin rash: Results of a survey among German oncologists. Onkologie 2010;33:94-98.
61. Micantonio T, Fargnoli MC, Ricevuto E et al. Efficacy of treatment with tetracyclines to prevent acneiform eruption secondary to cetuximab therapy. Arch Dermatol 2005;141:1173-1174.
62. Journagan S, Obadiah J. An acneiform eruption due to erlotinib: Prognostic implications and management. J Am Acad Dermatol 2006;54:358-360.
63. Eames T, Landthaler M, Karrer S. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor. Eur J Dermatol 2007;17:552-553.
64. Korman JB, Ward DB, Maize JC Jr. Papulopustular eruption associated with panitumumab. Arch Dermatol 2010;146:926-927.
65. Racca P, Fanchini L, Caliendo V et al. Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: Outcomes from an oncologic/ dermatologic cooperation. Clin Colorectal Cancer 2008;7:48-54.
66. Van Doorn R, Kirtschig G, Scheffer E et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002;147: 598-601.
67. Schalock PC, Zug KA. Acneiform reaction to erlotinib. Dermatitis 2007;18:230-231.
68. Satta R, Cuccuru MA, Pirodda C et al. Papulopustular eruption during cetuximab treatment. G Ital Dermatol Venereol 2008;143:87-88.
69. Tomkovà H, Kohoutek M, Zàbojníkovà M et al. Cetuximab-induced cutaneous toxicity. J Eur Acad Dermatol Venereol 2010;24:692-696.
70. Lacouture ME, Mitchell EP, Piperdi B et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:1351-1357.
71. Jatoi A, Rowland K, Sloan JA et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: Results of a placebocontrolled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008;113:847-853.
72. Deplanque G, Chavaillon J, Vergnenegre A et al. CYTAR: A randomized clinical trial evaluating the preventive effect of doxycycline on erlotinibinduced folliculitis in non-small cell lung cancer patients. J Clin Oncol 2010;28(15 suppl):A9019.
73. Scope A, Agero AL, Dusza SW et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximabassociated acne-like eruption. J Clin Oncol 2007;25: 5390-5396.
74. Walon L, Gilbeau C, Lachapelle JM. [Acneiform eruptions induced by cetuximab.] Ann Dermatol Venereol 2003;130:443-446. In French.
75. Matheis P, Socinski MA, Burkhart C et al. Treatment of gefitinib-associated folliculitis. J Am Acad Dermatol 2006;55:710-713.
76. DeWitt CA, Siroy AE, Stone SP. Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy. J Am Acad Dermatol 2007;56:500-505.
77. Boeck S, Hausmann A, Reibke R et al. Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Anticancer Drugs 2007;18:1109-1111.
78. Lacouture ME, Hwang C, Marymont MH et al. Temporal dependence of the effect of radiation on erlotinib-induced skin rash. J Clin Oncol 2007;25: 2140.
79. Amitay-Laish I, David M, Stemmer SM. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptortargeted therapy: An early and a late phase of papulopustular eruptions. The Oncologist 2010;15: 1002-1008.
80. Molinari E, De Quatrebarbes J, André T et al. Cetuximab-induced acne. Dermatology 2005;211: 330-333.
81. Hannoud S, Rixe O, Bloch J et al. [Skin signs associated with epidermal growth factor inhibitors.] Ann Dermatol Venereol 2006;133:239-242. In French.
82. de Noronha e Menezes NM, Lima R, Moreira A et al. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: A prospective and descriptive study of 19 patients. Eur J Dermatol 2009;19:248-251.
83. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
84. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359: 1757-1765.
85. Douillard JY, Shepherd FA, Hirsh V et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non small cell lung cancer: Data from the randomized phase III INTEREST trial. J Clin Oncol 2010;28:744-752.
86. Bezjak A, Tu D, Seymour L et al. Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006;24:3831-3837.
87. Wheatley-Price P, Ding K, Seymour L et al. Erlotinib for advanced non-small-cell lung cancer in the elderly: An analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:2350-2357.
88. Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-572.
89. Spigel DR, Lin M, O'Neill V et al. Final survival and safety results from a multicenter, openlabel, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer. Cancer 2008; 112:2749-2755.
90. Gibson TB, Ranganathan A, Grothey A. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 2006;6:29-31.
91. Siena S, Peeters M, Van Cutsem E et al. Association of progression-free survival with patientreported outcomes and survival: Results from a randomised phase 3 trial of panitumumab. Br J Cancer 2007;97:1469-1474.
92. Gridelli C, Butts C, Ciardiello F et al. An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/ gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced nonsmall-cell lung cancer: Treatment rationale and protocol dynamics of the TORCH trial. Clin Lung Cancer 2008;9:235-238.
93. RTOG 0522: A randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for stage III and IV head and neck carcinomas. Clin Adv Hematol Oncol 2007;5:79-81.
94. Venook AP, Blanke CD, Niedzwiecki D et al. Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: A phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma. Clin Colorectal Cancer 2005;5:292-294.
95. CALGB/SWOG C80405: A phase III trial of FOLFIRI or FOLFOX with bevacizumab or cetuximab or both for untreated metastatic adenocarcinoma of the colon or rectum. Clin Adv Hematol Oncol 2006;4:452-453.
96. Berlin J, Posey J, Tchekmedyian S et al. Panitumumab with irinotecan/leucovorin/5 fluorouracil for first line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2007;6:427-432.
97. Cascinu S, Berardi R, Labianca R et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: A randomised, multicentre, phase II trial. Lancet Oncol 2008;9:39-44.
98. Okines AF, Ashley SE, Cunningham D et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: Dose-finding study for the prospective multicenter, randomized, phase II/III REAL 3 trial. J Clin Oncol 2010;28:3945-3950.
99. Stephenson JJ, Gregory C, Burris H et al. An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors. Clin Colorectal Cancer 2009;8:29-37.
100. Weiner LM, Belldegrun AS, Crawford J et al. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 2008;14:502-508.
101. Pfeiffer P, Nielsen D, Bjerregaard J et al. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 2008;19:1141-1145.
102. Folprecht G, Gruenberger T, Bechstein WO et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial. Lancet Oncol 2010;11:38-47.
103. Vermorken JB, Mesia R, Rivera F et al. Platinum based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-1127.
104. Peeters M, Price TJ, Cervantes A et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:4706-4713.
105. Douillard JY, Siena S, Cassidy J et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 2010;28:4697-4705.
106. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003;290:2149-2158.
107. Herbst RS, Prager D, Hermann R et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899.
108. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 2004;22:777-784.
109. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794.
110. Stewart JS, Cohen EE, Licitra L et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 2009;27: 1864-1871.
111. Ocvirk J, Brodowicz T, Wrba F et al. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 2010;16:3133-3143.
112. Van Cutsem E, Siena S, Humblet Y et al. An open label, single arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2008;19:92-98.
113. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-671.
114. Herbst RS, Arquette M, Shin DM et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5578-5587.
115. Herbst RS, Kelly K, Chansky K et al. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J Clin Oncol 2010;28:4747-4754.
116. Belani CP, Schreeder MT, Steis RG et al. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advancedstage nonsmall cell lung cancer: A multicenter phase 2 study. Cancer 2008;113:2512-2517.
117. Baselga J, Trigo JM, Bourhis J et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5568-5577.
118. Lenz HJ, Van Cutsem E, Khambata-Ford S et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006;24:4914-4921.
119. Adams RA, Meade AM, Madi A et al. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br J Cancer 2009;100: 251-258.
120. Tol J, Koopman M, Rodenburg CJ et al. Arandomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in firstline advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 2008;19: 734-738.
121. Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311-2319.
122. Burtness B, Goldwasser MA, Flood W et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/ recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23:8646-8654.
123. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578.
124. Philip PA, Benedetti J, Corless CL et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010;28: 3605-3610.
125. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non small cell lung cancer (FLEX): An open label randomised phase III trial. Lancet 2009;373:1525-1531.
126. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-2048.
127. Lynch TJ, Patel T, Dreisbach L et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010;28:911-917.
128. Jackman DM, Yeap BY, Lindeman NI et al. Phase II clinical trial of chemotherapy-naive patients ≥70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007;25: 760-766.
129. Mok TS, Wu YL, Yu CJ et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2009;27:5080-5087.
130. West HL, Franklin WA, McCoy J et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 2006;24:1807-1813.
131. Natale RB, Bodkin D, Govindan R et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: Results from a two-part, double-blind, randomized phase II study. J Clin Oncol 2009;27:2523-2529.
132. Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced nonsmall-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-529.
133. Boeck S, Vehling-Kaiser U, Waldschmidt D et al. Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: An interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'. Anticancer Drugs 2010;21:94-100.
134. Kelly K, Chansky K, Gaspar LE et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008;26:2450-2456.
135. Lee DH, Park K, Kim JH et al. Randomized phase III trial of gefitinib versus docetaxel in nonsmall cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010;16:1307-1314.
136. Maruyama R, Nishiwaki Y, Tamura T et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008;26: 4244-4252.
137. Takeda K, Hida T, Sato T et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: Results of a west Japan Thoracic Oncology Group trial (WJTOG0203). J Clin Oncol 2010;28:753-760.
138. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
139. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
140. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362: 2380-2388.
141. Smith K, Leyden JJ. Safety of doxycycline and minocycline: A systematic review. Clin Ther 2005;27:1329-1342.
142. Ochsendorf F. Minocycline in acne vulgaris: Benefits and risks. Am J Clin Dermatol 2010;11: 327-341.
143. Fewer adverse effects with doxycycline than with minocycline. Prescrire Int 2009;18:213.
144. Poli F. Acne on pigmented skin. Int J Dermatol 2007;46(suppl 1):39-41.
145. Pierard-Franchimont C, Goffin V, Arrese JE et al. Lymecycline and minocycline in inflammatory acne: A randomized, double-blind intent-to-treat study on clinical and in vivo antibacterial efficacy. Skin Pharmacol Appl Skin Physiol 2002;15:112-119.
146. Bossuyt L, Bosschaert J, Richert B et al. Lymecycline in the treatment of acne: An efficacious, safe and cost-effective alternative to minocycline. Eur J Dermatol 2003;13:130-135.
147. Garner SE, Eady EA, Popescu C et al. Minocycline for acne vulgaris: Efficacy and safety. Cochrane Database Syst Rev 2003;(1):CD002086.
148. Oishi KJ, Garey JS, Burke BJ et al. Managing cutaneous side effects associated with erlotinib in head and neck cancer and non-small-lung cancer patient. J Clin Oncol 2006;24(18 suppl): 18538.
149. Perez-Soler R, Delord JP, Halpern A et al. HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. The Oncologist 2005;10:345-356.
150. Rukazenkov Y, Speake G, Marshall G et al. Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different? Anticancer Drugs 2009;20:856-866.